Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers

Gilead is staying mum about the TROPiCS-02 data, which is fueling speculation that the drug’s benefit may have been modest.

Cancer cells on scientific background.3d illustration
Gilead announced results of the Phase III TROPiCS-02 study of Trodelvy in HR+/HER2- metastatic breast cancer • Source: Shutterstock

While Gilead Sciences, Inc.’s Phase III TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) technically met its primary endpoint in third-line HR-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC), public statements by the company and a lack of details about progression-free survival (PFS) and overall survival (OS) data raised uncertainty about whether they would be enough to drive commercial adoption.

Gilead announced the study results on 7 March, but did not disclose any data, saying instead that the trial met...

Welcome to Scrip

Create an account to read this article

More from Strategy

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

More from Business

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.